Trading activity could slow due to reduced volume. The stock might come under pressure from manipulations trying to push the price lower.
The silver lining is this will be an opportunity to purchase shares at a reduced cost. But, unfortunately, not much volume to take advantage of.
So ‘dirt bids’ will likely not be tested. With the limited shares available to be purchased, it will be ‘first come, first served’.
Once again, there is no Path to remarkable levels of Personal Profit following that Plan. You can hold me to it.
As in the past, there are many that intend to hold their positions and perhaps add more shares. But buying is not so much dependent on the price. Depends on the volume.
Expect that higher share volumes will cost a premium. But some will get more shares anyway, before any news breaks. This may be the time for ‘better early than late’.
But please note, I advise no one to sell, to buy, or take actions of any kind. Caveat emptor.
Still waiting for the show to start. And I wish I knew the starting time. That would make it all much easier.
Spread the love. Be the first to like this post!
Recent GSPE News
- Quarterly Report (10-q) • Edgar (US Regulatory) • 02/14/2023 09:24:16 PM
- Annual Report (10-k) • Edgar (US Regulatory) • 12/29/2022 09:14:05 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/14/2022 08:14:38 PM
- Proxy Statement (definitive) (def 14a) • Edgar (US Regulatory) • 08/26/2022 08:05:56 PM
- Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) • Edgar (US Regulatory) • 08/12/2022 08:21:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/16/2022 09:17:00 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM